GlassScriptPhysician profile
Margaret Grand
NPI 1043209117
$5,662.00
in general payments reported to CMS, 2019-2025
20 companies · $788 in 2025
The $788 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,174 · 2020: $118 · 2021: $1,015 · 2022: $853 · 2023: $682 · 2024: $1,033 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311 · Entertainment: $186 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.88 |
| Entertainment | $186.48 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $999.80 | 2022-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $888.16 | 2020-2025 | Total30, Dailies Total1, Precision7 |
| Coopervision INC. | $848.42 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $759.65 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $359.61 | 2021 | |
| Optos, INC. | $312.53 | 2019-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Oyster Point Pharma, INC. | $311.42 | 2022-2024 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $240.12 | 2019-2022 | |
| Lkc Technologies, INC. | $216.47 | 2024-2025 | |
| Optovue, INC. | $180.32 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $110.50 | 2020-2022 | |
| Glaukos Corporation | $105.99 | 2023 | |
| Sight Sciences, INC. | $86.41 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $81.59 | 2020-2023 | Acuvue |
| Novartis Pharmaceuticals Corporation | $41.82 | 2020-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lombart Brothers, INC. | $32.79 | 2025 | Opd-III |
| Dompe US, INC. | $27.36 | 2025 | Oxervate |
| Allergan, INC. | $23.81 | 2022 | |
| Biotissue Holdings INC. | $19.57 | 2024 | |
| Amgen INC. | $15.66 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Grand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.